Compare Fluxion Biosciences vs Sword Bio
Customers evaluate the quality of Fluxion Biosciences's products using the following success metrics.
Overview
Fluxion Biosciences is 19 yrs old and is based in United States.
Fluxion Biosciences produces automated patch clamp technology and cell-based assay tools. Its products include ERASE-Seq for next-generation sequencing (NGS) analysis of cancer from a "liquid biopsy" blood sample, IsoFlux for circulating tumor cell analysis, and more. It was founded in 2005 and is based in Oakland, California. In August 2023, Fluxion Biosciences was acquired by Cell Microsystems. The terms of the transaction were not disclosed.
Sword Bio is 20 yrs old and is based in United States.
Sword Bio develops a medical data research platform designed to determine and monitor the value of biological markers. The platform uses a technology involving resonance Raman to aid in the performance of the assays offering medical research, drug discovery, and the provision of healthcare products and services. It was formerly known as Sword Diagnostics. The company was founded in 2004 and is based in Chicago, Illinois.
Demo Video
Leadership
Michelle Khine (Founder)
David Dingott (Chief Executive Officer)
Investors
Cell Microsystems, Paycheck Protection Program
Ellipsis Ventures, Turret Capital
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Fluxion Biosciences has not claimed their profile.
Work for Fluxion Biosciences? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Fluxion Biosciences?
Claim your profile now.
Information not available because Sword Bio has not claimed their profile.
Work for Sword Bio? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Sword Bio?
Claim your profile now.